OBJECTIVE: To determine the effects of primary antiphospholipid syndrome (PAPS)-derived anti-beta(2)GPI antibodies on gene expression in human umbilical vein endothelial cells (HUVEC) by gene profiling using microarrays. METHODS: Anti-beta(2)GPI antibodies purified from sera of patients with PAPS or control IgG isolated from normal subjects were incubated with HUVEC for 4 h before isolation of RNA and processing for hybridisation to Affymetrix Human Genome U133A-2.0 arrays. Data were analysed using a combination of the MAS 5.0 (Affymetrix) and GeneSpring (Agilent) software programmes. For selected genes microarray data were confirmed by real-time PCR analysis or at the protein level by ELISA. RESULTS: A total of 101 genes were found to be upregulated and 14 genes were downregulated twofold or more in response to anti-beta(2)GPI antibodies. A number of novel genes not previously associated with APS were induced, including chemokines CCL20, CXCL3, CX3CL1, CXCL5, CXCL2 and CXCL1, the receptors Tenascin C, OLR1, IL-18 receptor 1, and growth factors CSF2, CSF3 IL-6, IL1beta and FGF18. The majority of downregulated genes were transcription factors/signalling molecules including ID2. Quantitative real-time RT-PCR analysis confirmed the microarray results for selected genes (CSF3, CX3CL1, FGF18, ID2, SOD2, Tenascin C). CONCLUSIONS: This study reveals a complex gene expression response in HUVEC to anti-beta(2)GPI antibodies with multiple chemokines, pro-inflammatory cytokines, pro-thrombotic and pro-adhesive genes regulated by these antibodies in vitro. Some of these newly identified anti-beta(2)GPI antibody-regulated genes could contribute to the vasculopathy associated with this disease.
OBJECTIVE: To determine the effects of primary antiphospholipid syndrome (PAPS)-derived anti-beta(2)GPI antibodies on gene expression in human umbilical vein endothelial cells (HUVEC) by gene profiling using microarrays. METHODS: Anti-beta(2)GPI antibodies purified from sera of patients with PAPS or control IgG isolated from normal subjects were incubated with HUVEC for 4 h before isolation of RNA and processing for hybridisation to Affymetrix Human Genome U133A-2.0 arrays. Data were analysed using a combination of the MAS 5.0 (Affymetrix) and GeneSpring (Agilent) software programmes. For selected genes microarray data were confirmed by real-time PCR analysis or at the protein level by ELISA. RESULTS: A total of 101 genes were found to be upregulated and 14 genes were downregulated twofold or more in response to anti-beta(2)GPI antibodies. A number of novel genes not previously associated with APS were induced, including chemokines CCL20, CXCL3, CX3CL1, CXCL5, CXCL2 and CXCL1, the receptors Tenascin C, OLR1, IL-18 receptor 1, and growth factors CSF2, CSF3IL-6, IL1beta and FGF18. The majority of downregulated genes were transcription factors/signalling molecules including ID2. Quantitative real-time RT-PCR analysis confirmed the microarray results for selected genes (CSF3, CX3CL1, FGF18, ID2, SOD2, Tenascin C). CONCLUSIONS: This study reveals a complex gene expression response in HUVEC to anti-beta(2)GPI antibodies with multiple chemokines, pro-inflammatory cytokines, pro-thrombotic and pro-adhesive genes regulated by these antibodies in vitro. Some of these newly identified anti-beta(2)GPI antibody-regulated genes could contribute to the vasculopathy associated with this disease.
Authors: W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta Journal: Arthritis Rheum Date: 1999-07
Authors: J George; D Harats; B Gilburd; A Afek; Y Levy; J Schneiderman; I Barshack; J Kopolovic; Y Shoenfeld Journal: Circulation Date: 1999-05-04 Impact factor: 29.690
Authors: G Kaplanski; P Cacoub; C Farnarier; V Marin; R Grégoire; A Gatel; J M Durand; J R Harlé; P Bongrand; J C Piette Journal: Arthritis Rheum Date: 2000-01
Authors: M Boerma; L Forsberg; L Van Zeijl; R Morgenstern; U De Faire; C Lemne; D Erlinge; T Thulin; Y Hong; I A Cotgreave Journal: J Intern Med Date: 1999-08 Impact factor: 8.989
Authors: Daniel Teupser; Stephanos Pavlides; Marietta Tan; Jose-Carlos Gutierrez-Ramos; Roland Kolbeck; Jan L Breslow Journal: Proc Natl Acad Sci U S A Date: 2004-12-13 Impact factor: 11.205
Authors: D Nochy; E Daugas; D Droz; H Beaufils; J P Grünfeld; J C Piette; J Bariety; G Hill Journal: J Am Soc Nephrol Date: 1999-03 Impact factor: 10.121
Authors: Amber L Beitelshees; Christina L Aquilante; Hooman Allayee; Taimour Y Langaee; Gregory J Welder; Richard S Schofield; Issam Zineh Journal: Hum Genomics Date: 2012-08-02 Impact factor: 4.639
Authors: Eguzkine Ochoa; Mikel Iriondo; Ana Bielsa; Guillermo Ruiz-Irastorza; Andone Estonba; Ana M Zubiaga Journal: PLoS One Date: 2013-07-03 Impact factor: 3.240
Authors: Vera M Ripoll; Anastasia Lambrianides; Silvia S Pierangeli; Katie Poulton; Yiannis Ioannou; Wendy E Heywood; Kevin Mills; David S Latchman; David A Isenberg; Anisur Rahman; Ian P Giles Journal: Blood Date: 2014-10-09 Impact factor: 22.113